Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Stock Information for Cerus Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cerus Corporation

Cerus Corporation Announces First Quarter 2024 Financial Results
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update
Cerus Corporation to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.